BLFS · As filed with the SEC

Biolife Solutions balance sheet, by quarter

The statement as Biolife Solutions presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Unaudited Condensed Consolidated Balance Sheets · USD thousands

USD thousands	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025
Assets
Current assets:
Cash and cash equivalents	23,997	22,822	33,038	29,481
Available-for-sale securities, current portion	58,419	58,174	55,889	49,473
Accounts receivable, trade, net of allowance for credit losses of $16 and $22 as of June 30, 2026 and December 31, 2025, respectively	10,652	13,057	7,953	10,842
Inventories	35,591	32,834	30,155	27,825
Prepaid expenses and other current assets	6,539	6,335	9,526	8,945
Current assets, discontinued operations	—	—	0	—
Total current assets	135,198	133,222	136,561	126,566
Assets held for rent, net	—	—	—	5,164
Property and equipment, net	15,235	14,504	14,713	11,101
Operating lease right-of-use assets, net	8,644	7,113	7,466	7,633
Other assets	3,289	3,049	3,050	2,419
Available-for-sale securities, long-term	30,654	30,499	31,250	19,444
Equity investments	—	—	0	0
Intangible assets, net	3,654	3,932	4,257	7,450
Deferred tax assets, net	42,233	—	—	—
Goodwill	208,587	208,587	208,587	212,304
Long-term assets, discontinued operations	—	—	0	—
Total assets	447,494	400,906	405,884	392,081
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	2,482	3,750	1,486	2,890
Accrued expenses and other current liabilities	6,798	7,575	11,974	10,905
Sales taxes payable	2,074	2,113	2,279	3,681
Lease liabilities, operating, current portion	2,593	2,316	2,243	2,178
Debt, current portion	0	2,499	4,997	7,492
Current liabilities, discontinued operations	—	—	0	—
Total current liabilities	13,947	18,253	22,979	27,146
Lease liabilities, operating, long-term	13,145	10,042	10,657	11,007
Debt, long-term	—	—	0	0
Deferred tax liabilities	0	198	189	189
Other long-term liabilities	399	183	171	—
Long-term liabilities, discontinued operations	—	—	0	—
Total liabilities	27,491	28,676	33,996	38,342
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025	0	0	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 48,889,090 and 48,198,928 shares issued and outstanding, respectively, as of June 30, 2026 and December 31, 2025	49	49	48	48
Additional paid-in capital	713,571	710,811	711,404	704,327
Accumulated other comprehensive (loss) income, net of tax	(211)	(120)	132	130
Accumulated deficit	(293,406)	(338,510)	(339,696)	(350,766)
Total shareholders’ equity	420,003	372,230	371,888	353,739
Total liabilities and shareholders’ equity	447,494	400,906	405,884	392,081

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.